Close

Generic EpiPen to Hit Mylan (MYL) EPS by a Modest 2% - Leerink

Go back to Generic EpiPen to Hit Mylan (MYL) EPS by a Modest 2% - Leerink

BTIG Affirms Mylan (MYL) at 'Buy'; Generic EpiPen Highlights Challenges to U.S. Healthcare System

August 29, 2016 2:22 PM EDT

BTIG affirms Mylan (Nasdaq: MYL) with a Buy rating and $60 price target as the company moves to release a generic EpiPen.

Analyst Timothy Chiang commented today, While Mylan has dealt with much criticism from the media and politicians, we believe the measures the company has announced... More

Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand

August 29, 2016 6:06 AM EDT

Mylan N.V. (Nasdaq: MYL) announced that its U.S. subsidiary will launch the first generic to EpiPen Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"), of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton... More